Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...

Morning hypertension has been reported to be an important risk factor for cardiovascular events, and arterial stiffness bears a relationship with cardiovascular risk. The aim of this study was to ...

The results of the Valsartan/HCTZ Combination Therapy in Patients With Moderate to Severe Systolic Hypertension (VALOR) study [1] show that valsartan 160 mg once daily is safe and effective in older ...

The new year brings a new blood pressure medication recall. This time Aurobindo Pharma USA has recalled 80 lots of its Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan ...

Earlier this month, the FDA announced a voluntary recall of some valsartan-containing drugs after N-nitrosodimethylamine (NDMA) was found in the active pharmaceutical ingredients (API) manufactured by ...

Angiotensin II, the principal effector peptide of the renin-angiotensin-aldosterone system (RAAS), has potent vasoconstrictive and other effects that can lead to cardiac and renal complications.

It is not known whether drugs that block the renin–angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. In this double-blind, ...

Since July 2018, there have been a string of recalls related to three common generic heart drugs — losartan, irbesartan and valsartan — due to the detection of probable human carcinogens. July 13, ...

Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, 90-count bottles, lot. Nos. 20x006 and 21x006, expiration 11/2018. Amlodipine, Valsartan, and Hydrochlorothiazide Tablets ...

Amlodipine (as besylate) 5 mg, valsartan 160 mg; tabs. Exforge combines two antihypertensive drugs that have complementary mechanisms of action: amlodipine, a calcium (Ca+) channel blocker, and ...

Please provide your email address to receive an email when new articles are posted on . Declines in estimated glomerular filtration rate after transition to sacubitril/valsartan for HF are mild and ...